AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation

Inclusion Criteria: * Adult recipients aged between 18 to 70 * Primary renal transplantation * Cadaver or living transplantation or living (non HLA identical) donor with compatible ABO blood type. * absence of anti-LHA antibodies in lymphocytotoxicity and Luminex * Negative cross-match in cytotoxicity * Negative pregnancy test for female patients of childbearing potential, and agreement to practice effective birth control during the study Exclusion Criteria: * Combined transplantation * Renal bigraft * History of any other transplantation * Receiving a graft from a non-heart-beating donor. * Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation * Patient who received within one month prior to study an inductor of CYP50 3A or requiring during the study an inhibitor of CYP50 3A or of P-gp. * Significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer * Subject or donor known to be HIV positive * Active viral hepatitis (VHB, VHC) at randomisation * Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, or mycophenolate mofetil or any of the product excipients * Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully. * Current participation in any other clinical study * Any clinical condition which, in th…